203 related articles for article (PubMed ID: 2436247)
21. L-deprenyl in Alzheimer's disease. Preliminary evidence for behavioral change with monoamine oxidase B inhibition.
Tariot PN; Cohen RM; Sunderland T; Newhouse PA; Yount D; Mellow AM; Weingartner H; Mueller EA; Murphy DL
Arch Gen Psychiatry; 1987 May; 44(5):427-33. PubMed ID: 3107514
[TBL] [Abstract][Full Text] [Related]
22. Analysis of monoamines in the cerebrospinal fluid of Chinese patients with Alzheimer's disease.
Liu HC; Yang JC; Chang YF; Liu TY; Chi CW
Ann N Y Acad Sci; 1991; 640():215-8. PubMed ID: 1723257
[TBL] [Abstract][Full Text] [Related]
23. Effects of monoamine oxidase A inhibition on plasma biogenic amine metabolites in depressed patients.
Markianos M; Alevizos B; Hatzimanolis J; Stefanis C
Psychiatry Res; 1994 Jun; 52(3):259-64. PubMed ID: 7527564
[TBL] [Abstract][Full Text] [Related]
24. Neuropsychological test performance and CSF levels of monoamine metabolites in healthy volunteers and patients with Alzheimer's dementia.
Nybäck H; Nyman H; Schalling D
Acta Psychiatr Scand; 1987 Dec; 76(6):648-56. PubMed ID: 2450445
[TBL] [Abstract][Full Text] [Related]
25. Effect of long-term treatment with selective monoamine oxidase A and B inhibitors on dopamine release from rat striatum in vivo.
Lamensdorf I; Youdim MB; Finberg JP
J Neurochem; 1996 Oct; 67(4):1532-9. PubMed ID: 8858937
[TBL] [Abstract][Full Text] [Related]
26. Significance of decreased lumbar CSF levels of HVA and 5-HIAA in Alzheimer's disease.
Blennow K; Wallin A; Gottfries CG; Lekman A; Karlsson I; Skoog I; Svennerholm L
Neurobiol Aging; 1992; 13(1):107-13. PubMed ID: 1371850
[TBL] [Abstract][Full Text] [Related]
27. The effect of R-(-)-deprenyl in de novo parkinsonian patients pretreated with levodopa and decarboxylase inhibitor correlated to depression and MHPG, HIAA and HVA levels in the cerebrospinal fluid.
Przuntek H; Kuhn W; Kraus P
Acta Neurol Scand Suppl; 1989; 126():153-6. PubMed ID: 2482649
[TBL] [Abstract][Full Text] [Related]
28. CSF monoamine metabolites in old age dementias.
Parnetti L; Gaiti A; Reboldi GP; Santucci C; Mecocci P; Brunetti M; Cadini D; Senin U
Mol Chem Neuropathol; 1992; 16(1-2):143-57. PubMed ID: 1381590
[TBL] [Abstract][Full Text] [Related]
29. Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with l-deprenyl.
Riederer P; Youdim MB
J Neurochem; 1986 May; 46(5):1359-65. PubMed ID: 2420928
[TBL] [Abstract][Full Text] [Related]
30. Monoamine neurotransmitter interactions in drug-free and neuroleptic-treated schizophrenics.
Hsiao JK; Colison J; Bartko JJ; Doran AR; Konicki PE; Potter WZ; Pickar D
Arch Gen Psychiatry; 1993 Aug; 50(8):606-14. PubMed ID: 7688209
[TBL] [Abstract][Full Text] [Related]
31. Higher cerebrospinal fluid MHPG in subjects with dementia of the Alzheimer type. Relationship with cognitive dysfunction.
Sheline YI; Miller K; Bardgett ME; Csernansky JG
Am J Geriatr Psychiatry; 1998; 6(2):155-61. PubMed ID: 9581211
[TBL] [Abstract][Full Text] [Related]
32. Vasopressin levels in CSF of Alzheimer patients: correlations with monoamine metabolites and neuropsychological test performance.
Jolkkonen J; Helkala EL; Kutvonen R; Lehtinen M; Riekkinen PJ
Psychoneuroendocrinology; 1989; 14(1-2):89-95. PubMed ID: 2471986
[TBL] [Abstract][Full Text] [Related]
33. Biogenic amine metabolites in human CSF after hypoxia due to cardiac arrest.
Odink J; Kärkelä J; Thissen JT; Marnela KM
Acta Neurol Scand; 1989 Jul; 80(1):6-11. PubMed ID: 2476907
[TBL] [Abstract][Full Text] [Related]
34. Selective attention in Alzheimer's disease: CSF correlates of behavioral impairments.
Freed DM; Corkin S; Growdon JH; Nissen MJ
Neuropsychologia; 1988; 26(6):895-902. PubMed ID: 2461537
[TBL] [Abstract][Full Text] [Related]
35. Simultaneous determination of 3-methoxy-4-hydroxyphenylglycol, 5-hydroxyindoleacetic acid, and homovanillic acid in cerebrospinal fluid with high-performance liquid chromatography using electrochemical detection.
Scheinin M; Chang WH; Kirk KL; Linnoila M
Anal Biochem; 1983 May; 131(1):246-53. PubMed ID: 6193730
[TBL] [Abstract][Full Text] [Related]
36. Effects of deprenyl on monoamine oxidase and neurotransmitters in the brains of MPTP-treated aging mice.
Gupta M; Wiener HL
Neurochem Res; 1995 Apr; 20(4):385-9. PubMed ID: 7544444
[TBL] [Abstract][Full Text] [Related]
37. Clinical and biochemical responses to therapy in Alzheimer's disease and multi-infarct dementia.
Corona GL; Cucchi ML; Frattini P; Santagostino G; Schinelli S; Romani A; Pola A; Zerbi F; Savoldi F
Eur Arch Psychiatry Neurol Sci; 1989; 239(2):79-86. PubMed ID: 2478368
[TBL] [Abstract][Full Text] [Related]
38. Monoamine metabolites in cerebrospinal fluid and serotonin uptake inhibition during treatment with chlorimipramine.
Asberg M; Ringberger VA; Sjöqvist F; Thorén P; Träskman L; Tuck JR
Clin Pharmacol Ther; 1977 Feb; 21(2):201-7. PubMed ID: 13959
[TBL] [Abstract][Full Text] [Related]
39. Monoamine metabolites in ventricular CSF of children with posterior fossa tumors: correlation with tumor histology and cognitive functioning.
Varela M; Alexiou GA; Liakopoulou M; Papakonstantinou E; Pitsouni D; Alevizopoulos GA
J Neurosurg Pediatr; 2014 Apr; 13(4):375-9. PubMed ID: 24559277
[TBL] [Abstract][Full Text] [Related]
40. Decreased monoamine metabolites in frontotemporal dementia and Alzheimer's disease.
Sjögren M; Minthon L; Passant U; Blennow K; Wallin A
Neurobiol Aging; 1998; 19(5):379-84. PubMed ID: 9880039
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
